| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
LivaNova PLC$78.68
-0.03 (-0.04%)
C 58Pipeline Score MedTech · Commercial
Market Cap
4.06 B
EPS
1.96
P/E Ratio
38.11 $
Value Trade
52.05 M
SEC Financials
Q1 2026Dilution Risk
Revenue
362.26 M
R&D Expenses
58.70 M
Operating CF
15.22 M
Total Assets
2.52 B
Total Liabilities
1.31 B
Equity
1.21 B
D/E Ratio
12,345
3.81 %
Week
13.94 %
1 Month
8.64 %
3 Month
36.34 %
6 Month
-11.02 %
5 Year
6.98 %
All Time
Cash Data
Cash Position
542.71 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
576.24 K
52 Week Range
41.02 - 74.41
% held by Insiders
0.48 %
% held by Institutions
110 %
Enterprise Value
3.86 B
Total Shares
54.95 M
Short %
6.1 %
Float Shares
54.73 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C58
Pipeline Score $5.6B
Pipeline ValueValuation Signal
8
Drugs Scored4.6x
rNPV / MCap Top 88%
Small Cap (rank 110 of 905)
Percentile RankLivaNova PLC carries a moderate pipeline score (58/100), with $8.6B risk-adjusted pipeline value, led by CRT-SonR 9770 in Heart Failure (Phase 3), across $52B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRT-SonR 9770 Unknown | Heart Failure | Phase 3 | NCT01169272 | 46% | $2.4B | COMPLETED | 100 | - | - | Jun 1, 2012 | - | Jun 18, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LIVN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LIVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIVN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LIVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LIVNLivaNova to Announce Second-Quarter 2026 Results
LivaNova is set to announce its second-quarter results for 2026. The announcement is anticipated by investors and stakeholders. Further details regarding the financial performance and strategic outlook will be disclosed at that time.
Read more →LIVNLivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
LivaNova has reported an 84.5% cumulative response rate from its PolySync programming in the OSPREY study targeting obstructive sleep apnea. This promising outcome suggests potential advancements in the treatment of this condition. The results may pave the way for further developments in therapeutic options for patients.
Read more →LIVNJette Nygaard-Andersen Joins LivaNova Board as a New Director
Jette Nygaard-Andersen has been appointed as a new director on the board of LivaNova. This addition to the board is part of LivaNova's ongoing efforts to enhance its leadership team. The company aims to leverage her expertise in the biopharma sector to drive future growth.
Read more →LIVNLivaNova Appoints Anne Liddy as Chief Legal Officer
LivaNova has appointed Anne Liddy as its new Chief Legal Officer. This leadership change is part of the company's ongoing efforts to strengthen its executive team. Liddy brings extensive legal experience to the role, which may enhance the company's legal strategies moving forward.
Read more →LIVNLivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova has appointed Stefano Folli to lead its Cardiopulmonary Business Unit. This leadership change aims to enhance the company's focus on cardiopulmonary products and strategies. Further details regarding Folli's plans or the impact of this appointment have not been disclosed.
Read more →LIVNLivaNova to Present at Goldman Sachs Global Healthcare Conference in June 2026
LivaNova PLC announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 8, 2026. CEO Vladimir Makatsaria, CFO Alex Shvartsburg, and Chief Strategy Officer Phil Kowalczyk will engage in a fireside chat. The event will be available via webcast, with a replay accessible shortly after.
Read more →LIVNLivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LivaNova is scheduled to present at the Goldman Sachs Global Healthcare Conference in June. This event will provide an opportunity for the company to share insights and updates with investors and industry stakeholders. Further details about the presentation have not been disclosed.
Read more →LIVNLivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC reported a strong first quarter for 2026, with revenue rising to $362.3 million, a 14.3% increase from the previous year. The company also raised its full-year guidance for revenue growth and adjusted diluted earnings per share. Notably, LivaNova received FDA premarket approval for its aura6000™ System, marking a significant advancement in its product offerings for obstructive sleep apnea.
Read more →LIVNAnnals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
LivaNova's OSPREY clinical study published in the Annals of Internal Medicine shows that proximal hypoglossal nerve stimulation (pHGNS) significantly improves outcomes for patients with moderate to severe obstructive sleep apnea (OSA). The study, which involved a diverse patient population, demonstrated sustained improvements in apnea-hypopnea index, sleep quality, and patient-reported outcomes over 12 months. LivaNova plans to commercialize its aura6000 system for OSA treatment following FDA approval.
Read more →LIVNLivaNova to Announce First-Quarter 2026 Results
LivaNova PLC will announce its first-quarter 2026 results during a conference call on May 6, 2026. The call will take place at 1 p.m. London time and will be accessible via audiocast and telephone. A replay will be available on the company's website following the event.
Read more →LIVNLivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
LivaNova PLC reported strong financial results for Q4 and full-year 2025, highlighting double-digit revenue growth and improved operating margins. The company anticipates continued growth in 2026, projecting revenue increases of 6-7% and adjusted diluted earnings per share between $4.15 and $4.25. Despite a significant loss per share due to environmental liabilities, LivaNova remains optimistic about its future prospects in the OSA market.
Read more →LIVNLivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LivaNova PLC will hold a conference call on February 25, 2026, to discuss its fourth-quarter and full-year 2025 results. The results will be released prior to the call, which will be accessible via audiocast and telephone. A replay will be available on the company's website after the event.
Read more →LIVNLivaNova to Present at J.P. Morgan Healthcare Conference in January 2026
LivaNova PLC has announced its participation in the J.P. Morgan 44th Annual Healthcare Conference in January 2026. CEO Vladimir Makatsaria and CFO Alex Shvartsburg will engage in a fireside chat, which will be accessible via webcast. This event highlights LivaNova's commitment to sharing its vision and developments with a global audience.
Read more →LIVNLivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
LivaNova PLC has appointed Lucile Blaise as the Global Head of Commercialization for Obstructive Sleep Apnea, effective December 1. With over 25 years of experience in the medtech industry, Blaise aims to enhance patient access and drive growth in the OSA market. She previously held significant roles at ResMed, contributing to her expertise in sleep therapy.
Read more →LIVNLivaNova PLC Historical Recast of Segment Data Unaudited
LivaNova PLC has published an historical recast of segment data that reveals a mixed financial performance across various periods for 2022 and 2023. While total net revenues, particularly in the neuromodulation segment, show positive trends compared to the prior year, operating losses have been recorded, especially in certain quarters due to increased expenses. The data outlines both revenue growth and losses, illustrating the company's ongoing financial challenges in the market.
Read more →LIVNLivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility Announcement follows closing of underwritten offering of ordinary shares London
LivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility Announcement follows closing of underwritten offering of ordinary shares London, August 16, 2021 - LivaNova PLC (NASDAQ LIVN), a market-leading medical technology a
Read more →LIVNLivaNova Prices Offering of Ordinary Shares London
LivaNova Prices Offering of Ordinary London, August 3, 2021 - LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that it has priced an underwritten offering of 3,636,364 ordinary shares at a price to the public of $82.50 per
Read more →LIVNLivaNova Announces Offering of Ordinary Shares London
LivaNova Announces Offering of Ordinary Shares London, August 2, 2021 - LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has commenced an underwritten offering of $300 million of its ordinary shares. LivaNova also inten
Read more →LIVNLivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital Additional local business closings to occur later this year London
LivaNova Completes Initial Closing of Heart Valve Business to Additional local business closings to occur later this year London, June 1, 2021 - LivaNova PLC (NASDAQ LIVN), a market-leading medical technology and innovation company, today announced it has successfully completed
Read more →LIVNLivaNova Announces Board Appointment and Board Leadership Changes London
LivaNova Announces Board Appointment and Board Leadership Changes London, December 7, 2020 - LivaNova PLC (NASDAQ LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company's governance. Todd Schermerhorn has been
Read more →LIVNLivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business London
LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business London, December 3, 2020 - LivaNova PLC (NASDAQ LIVN), a market-leading medical technology and innovation company, and Gyrus Capital (Gyrus), an investment firm dedicated to investments in t
Read more →LIVNLivaNova Announces Pricing of Private Offering of $250 Million of 3.00% Cash Exchangeable Senior Notes Due 2025 London
LivaNova Announces Pricing of Private Offering of $250 Million of 3.00% Cash Exchangeable Senior Notes Due 2025 London, June 12, 2020 LivaNova PLC (NASDAQ:LIVN) ( LivaNova ) today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senio
Read more →LIVNLivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes London
LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes London, June 11, 2020 LivaNova PLC (NASDAQ:LIVN) ( LivaNova ) today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 202
Read more →LIVNLivaNova Reports Fourth Quarter and Full-Year 2019 Results London
LivaNova Reports Fourth Quarter and Full-Year 2019 Results London, February 26, 2020 - LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019. For the fourth quarter o
Read more →LIVNLivaNova Reports Preliminary Unaudited First Quarter 2019 Revenue Results London
LivaNova Reports Preliminary Unaudited First Quarter 2019 London, April 5, 2019 - LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced preliminary unaudited revenue results for the quarter ended March 31, 2019. Preliminary First Quarter 2019
Read more →LIVNLivaNova Reports Preliminary Unaudited First Quarter 2019
LivaNova Reports Preliminary Unaudited First Quarter 2019 London, April 5, 2019 - LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced preliminary unaudited revenue results for the quarter ended March 31, 2019. Preliminary First Quarter 2019
Read more →LIVNLivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S.
LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device London, March 29, 2019 - LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 perc
Read more →LIVNLivaNova Recognizes Final Decision from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression Company plans to submit
LivaNova Recognizes Final Decision from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression Company plans to submit clinical study protocol for CMS consideration London, February 15, 2
Read more →LIVNN EWS RELEASE LivaNova Comments on the U.S. Centers for Medicare & Medicaid Services' Reconsideration of its National Coverage Determination for VNS Therapy for Treatment-Resistant Depression London
LivaNova Comments on the U.S. Centers for Medicare & Medicaid Services' Reconsideration of its National Coverage Determination for VNS Therapy for Treatment-Resistant Depression London, May 30, 2018 - LivaNova PLC (NASDAQ:LIVN) ("LivaNova" or the "Company"), a market-leading me
Read more →LIVNLivaNova Completes Sale of Cardiac Rhythm Management Business to MicroPort Scientific Corporation London, April 30 , 2018 LivaNova PLC (NASDAQ:LIVN) ( LivaNova or the Company ), a market-leading medical tech
LivaNova Completes Sale of Cardiac Rhythm Management Business to MicroPort Scientific Corporation London, April 30, 2018 LivaNova PLC (NASDAQ:LIVN) ( LivaNova or the Company ), a market-leading medical technology company, today announced it has successfully completed the dives
Read more →LIVNLivaNova Completes Acquisition of TandemLife London
LivaNova Completes Acquisition of TandemLife London, April 4, 2018 LivaNova PLC (NASDAQ:LIVN) ( LivaNova or the Company ), a market-leading medical technology company, today announced it closed its acquisition of TandemLife. Previously, on Feb. 14, LivaNova announced its intent
Read more →LIVNLivaNova to Acquire ImThera Medical, Inc.
LivaNova to Acquire ImThera Medical, Inc. Company will enter Obstructive Sleep Apnea space, enhancing its portfolio of Neuromodulation treatments and therapies London, Dec. 5, 2017 - LivaNova PLC (NASDAQ:LIVN) ("LivaNova" or the "Company"), a market-leading medical technology c
Read more →LIVNLivaNova to Acquire ImThera Medical, Inc. Company will enter Obstructive Sleep Apnea space, enhancing its portfolio of Neuromodulation treatments and therapies London
LivaNova to Acquire ImThera Medical, Inc. Company will enter Obstructive Sleep Apnea space, enhancing its portfolio of Neuromodulation treatments and therapies London, Dec. 5, 2017 LivaNova PLC (NASDAQ:LIVN) ( LivaNova or the Company ), a market-leading medical technology compa
Read more →LIVNLivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million London and Shanghai
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million London and Shanghai, Nov. 20, 2017 LivaNova PLC (NASDAQ:LIVN) ( LivaNova ) and MicroPort Scientific Corporation (HK:00853
Read more →LIVNLivaNova to Explore Strategic Options for Cardiac Rhythm Management Business Franchise London
LivaNova to Explore Strategic Options for Cardiac Rhythm Management Business Franchise London, September 14, 2017 LivaNova PLC (NASDAQ:LIVN) ( LivaNova or the Company ), a market-leading medical technology and innovation company, today announced it is exploring strategic optio
Read more →LIVNLivaNova PLC Announces Chief Financial Officer Resignation London
LivaNova PLC Announces Chief Financial Officer Resignation London, March 31, 2017 - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, today announced its Chief Financial Officer, Vivid Sehgal, is leav
Read more →LIVNLivaNova Reports Fourth Quarter and Full-Year 2016 Results London
LivaNova Reports Fourth Quarter and Full-Year 2016 Results London, March 1, 2017 - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, today reported results for the fourth quarter and full year ended
Read more →LIVNLivaNova Reports Third Quarter 2016 Results
LivaNova PLC reported its third-quarter results for 2016, showing a 3.2% increase in worldwide sales to $295 million. Despite a loss per share of $0.03 on a GAAP basis, adjusted earnings per share reached $0.78. The company faced challenges in its Cardiac Surgery segment but reported strong performances in its Neuromodulation and Cardiac Rhythm Management divisions. LivaNova is adjusting its sales guidance for the year, expecting revenue growth in the 1-2% range.
Read more →LIVNLivaNova PLC Announces CEO Transition: Damien McDonald to Succeed André-Michel Ballester
LivaNova PLC has appointed Damien McDonald as its new CEO, effective January 1, 2017, succeeding André-Michel Ballester. McDonald, previously the COO, brings extensive experience from Danaher Corporation and Zimmer. The board expressed confidence in his ability to lead LivaNova's mission of improving global health. Ballester's tenure is acknowledged for successfully merging two companies into a stronger entity.
Read more →LIVNLivaNova Reports Third Quarter 2016 Results London
LivaNova Reports Third Quarter 2016 Results London, November 2, 2016 - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, today reported results for the third quarter ended September 30, 2016. For the
Read more →LIVNLivaNova PLC to Present at the Credit Suisse Annual Healthcare Conference
LivaNova PLC announced its participation in the Credit Suisse Annual Healthcare Conference, scheduled for November 8, 2016. CEO André-Michel Ballester and CFO Vivid Sehgal will discuss the company's innovations and strategies. The event will be accessible via a live audiocast, with a replay available for 90 days post-event.
Read more →LIVNLivaNova to Host Conference Call for Third-Quarter 2016 Results
LivaNova PLC will host a conference call on November 2, 2016, to discuss its third-quarter results. The results will be released before the U.S. market opens. A live webcast will be available, and listeners are encouraged to log in early. A replay will be accessible for 90 days post-call.
Read more →LIVNLivaNova PLC Announces Participation in 30th EACTS Annual Meeting
LivaNova PLC announced its participation in the 30th EACTS Annual Meeting in Barcelona. The company will showcase significant milestones in its Cardiac Surgery Business Unit and host symposiums on innovative surgical techniques. LivaNova aims to simplify procedures to enhance patient outcomes and resource allocation in hospitals.
Read more →LIVNLivaNova Launches Next Generation ICD and CRT-D Devices in the United States
LivaNova has launched its next-generation PLATINIUM range of implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds) in the U.S. These devices are designed for extended longevity, reducing the need for replacement surgeries. The innovative technology ensures low energy consumption and improved patient comfort, addressing critical needs in cardiac care.
Read more →LIVNLivaNova Reports Second Quarter 2016 Results London
LivaNova Reports Second Quarter 2016 Results London, August 3, 2016 - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, today reported results for the second quarter ended June 30, 2016. For the seco
Read more →LIVNLivaNova PLC Names Chief Operating Officer London
LivaNova PLC Names Chief Operating Officer London, August 1, 2016 - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, following its announcement of a refined business implementation model and related
Read more →LIVNLivaNova PLC Names Andrea L. Saia to its Board of Directors London
LivaNova PLC Names Andrea L. Saia to its Board of Directors London, July 28, 2016 - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, today announced that Andrea L. Saia has been elected to its board
Read more →LIVNLivaNova PLC Sets Operating Model and Supporting Organization London
LivaNova PLC Sets Operating Model and Supporting Organization London, July 6, 2016 - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology company, today announced a new organizational structure designed to strengthen execution
Read more →LIVNLivaNova Reports First Quarter 2016 Results London
LivaNova Reports First Quarter 2016 Results London, May 4, 2016 - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a market-leading medical technology and innovation company, today reported results for the first quarter ended March 31, 2016. For the first qu
Read more →LIVNLivaNova Reports 2015 Annual and Fourth Quarter Financial Results Provides Fiscal 2016 Guidance London
LivaNova Reports 2015 Annual and Fourth Quarter Financial Results Provides Fiscal 2016 Guidance London, February 24, 2016; 6:00 AM CT - LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a global medical technology company, today announced 2015 financial resul
Read more →LIVNLIVANOVA RECEIVES REGULATORY APPROVAL IN JAPAN FOR KORA 250 WORLD'S SMALLEST FULL BODY MRI CONDITIONAL PACING SYSTEM WITH ITS UNIQUE COMBINATION OF SMALL SIZE, EXTENDED LONGEVITY, AND PROPRIETARY TECHNOLOGI
LIVANOVA RECEIVES REGULATORY APPROVAL IN JAPAN FOR KORA 250 WORLD'S SMALLEST FULL BODY MRI CONDITIONAL PACING SYSTEM WITH ITS UNIQUE COMBINATION OF SMALL SIZE, EXTENDED LONGEVITY, AND PROPRIETARY TECHNOLOGIES DESIGNED TO IMPROVE PATIENT OUTCOMES, KORA 250 ENABLES PATIENTS TO UN
Read more →LIVNLivaNova PLC Announces Management Change LONDON
LivaNova PLC Announces Management Change LONDON, January 13, 2016 -- LivaNova, PLC (NASDAQ:LIVN; LSE:LIVN) (the "Company"), today announced a change to the leadership of the Neuromodulation Business Unit. Effective immediately, Jason Richey has been appointed President of the N
Read more →LIVNLivaNova PLC Announces Approval of Perceval LONDON
LivaNova PLC Announces Approval of Perceval LONDON, January 11, 2016 -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) (the "Company") announced that, on January 8, 2016, the Company received approval from the United States Food and Drug Administration ("FDA") for the Perceval Sutureless
Read more →LIVNSORIN WARNING LETTER ex99_1.htm
SORIN WARNING LETTER ex99_1.htm
Read more →LIVNSORIN AND CYBERONICS ANNOUNCE APPOINTMENT OF LIVANOVA S CHIEF FINANCIAL OFFICER Milan, Italy and Houston, TX
SORIN AND CYBERONICS ANNOUNCE APPOINTMENT OF LIVANOVA S CHIEF FINANCIAL OFFICER Milan, Italy and Houston, TX, September 10, 2015 Sorin S.p.A., (MTA; Reuters Code: SORN.MI, Sorin ), a global medical device company and a leader in the treatment of cardiovascular diseases, and Cy
Read more →Competitive Position
How LIVN ranks across every disease it competes inCompetitive Position is a premium feature
See how LIVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial